Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 18;8(1):13978.
doi: 10.1038/s41598-018-32264-x.

Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies

Affiliations

Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies

Santiago Guerrero et al. Sci Rep. .

Abstract

Over the past decades, consistent studies have shown that race/ethnicity have a great impact on cancer incidence, survival, drug response, molecular pathways and epigenetics. Despite the influence of race/ethnicity in cancer outcomes and its impact in health care quality, a comprehensive understanding of racial/ethnic inclusion in oncological research has never been addressed. We therefore explored the racial/ethnic composition of samples/individuals included in fundamental (patient-derived oncological models, biobanks and genomics) and applied cancer research studies (clinical trials). Regarding patient-derived oncological models (n = 794), 48.3% have no records on their donor's race/ethnicity, the rest were isolated from White (37.5%), Asian (10%), African American (3.8%) and Hispanic (0.4%) donors. Biobanks (n = 8,293) hold specimens from unknown (24.56%), White (59.03%), African American (11.05%), Asian (4.12%) and other individuals (1.24%). Genomic projects (n = 6,765,447) include samples from unknown (0.6%), White (91.1%), Asian (5.6%), African American (1.7%), Hispanic (0.5%) and other populations (0.5%). Concerning clinical trials (n = 89,212), no racial/ethnic registries were found in 66.95% of participants, and records were mainly obtained from Whites (25.94%), Asians (4.97%), African Americans (1.08%), Hispanics (0.16%) and other minorities (0.9%). Thus, two tendencies were observed across oncological studies: lack of racial/ethnic information and overrepresentation of Caucasian/White samples/individuals. These results clearly indicate a need to diversify oncological studies to other populations along with novel strategies to enhanced race/ethnicity data recording and reporting.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Racial/Ethnic disparities in cancer research. Racial/ethnic inclusion was studied in several aspects of oncological research, from cell lines and patient-derived xenografts to biobanking, genomics and clinical trials.

References

    1. Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–307. doi: 10.1038/nature11003. - DOI - PMC - PubMed
    1. Felmeister AS, Masino AJ, Rivera TJ, Resnick AC, Pennington JW. The biorepository portal toolkit: an honest brokered, modular service oriented software tool set for biospecimen-driven translational research. BMC Genomics. 2016;17:434. doi: 10.1186/s12864-016-2797-9. - DOI - PMC - PubMed
    1. Hudson (Chairperson) TJ, et al. International network of cancer genome projects. Nature. 2010;464:993–998. doi: 10.1038/nature08987. - DOI - PMC - PubMed
    1. Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery — past, present and future. Nat. Rev. Drug Discov. 2014;13:588–602. doi: 10.1038/nrd4366. - DOI - PubMed
    1. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer. 2006;6:813–823. doi: 10.1038/nrc1951. - DOI - PubMed

MeSH terms